AEON
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.02 | $0 | -$4M |
| 2026 Q1 | -0.29 | $0 | -$3M |
| 2025 Q4 | -3.07 | $0 | -$5M |
| 2025 Q3 | -0.39 | $0 | -$3M |
| 2025 Q2 | -0.60 | $0 | -$2M |
| 2025 Q1 | 2.28 | $0 | -$8M |
| 2024 Q4 |
| 3.76 |
| $0 |
| -$621,000 |
| 2024 Q3 | -11.24 | $0 | -$3M |